ADORA2A and neoplasm: To further improve the efficacy of tumor immunotherapy, many inhibitors of the CD39‐CD73‐A2AR pathway have been developed.[23, 24, 25, 26] AZD4635 is an A2AR antagonist with high affinity and specificity for A2AR.